tradingkey.logo


tradingkey.logo


Candel Therapeutics Inc

CADL
5.860USD
-0.080-1.35%
取匕時間 ET15分遅れの株䟡
321.69M時䟡総額
損倱額盎近12ヶ月PER


Candel Therapeutics Inc

5.860
-0.080-1.35%

詳现情報 Candel Therapeutics Inc 䌁業名

Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.

Candel Therapeutics Incの䌁業情報


䌁業コヌドCADL
䌚瀟名Candel Therapeutics Inc
䞊堎日Jul 27, 2021
最高経営責任者「CEO」Tak (Paul Peter)
埓業員数38
蚌刞皮類Ordinary Share
決算期末Jul 27
本瀟所圚地117 Kendrick Street,
郜垂NEEDHAM
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号02494
電話番号16179165445
りェブサむトhttps://www.candeltx.com/
䌁業コヌドCADL
䞊堎日Jul 27, 2021
最高経営責任者「CEO」Tak (Paul Peter)

Candel Therapeutics Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Christopher (Chris) Martell
Mr. Christopher (Chris) Martell
Independent Director
Independent Director
435.51K
--
Dr. Paul Peter Tak, M.D., Ph.D.
Dr. Paul Peter Tak, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
268.57K
+18.97%
Dr. Francesca Barone, M.D., Ph.D.
Dr. Francesca Barone, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
100.81K
+4.44%
Mr. Charles Schoch
Mr. Charles Schoch
Chief Financial Officer
Chief Financial Officer
43.39K
+14.07%
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
Independent Director
Independent Director
38.03K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00K
--
Dr. Edward J. Benz, Jr., M.D.
Dr. Edward J. Benz, Jr., M.D.
Independent Director
Independent Director
--
--
Ms. Seshu Tyagarajan, Ph.D.
Ms. Seshu Tyagarajan, Ph.D.
Chief Technical and Development Officer
Chief Technical and Development Officer
--
--
Mr. Paul B. Manning
Mr. Paul B. Manning
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. W. Garrett Nichols, M.D.
Dr. W. Garrett Nichols, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Christopher (Chris) Martell
Mr. Christopher (Chris) Martell
Independent Director
Independent Director
435.51K
--
Dr. Paul Peter Tak, M.D., Ph.D.
Dr. Paul Peter Tak, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
268.57K
+18.97%
Dr. Francesca Barone, M.D., Ph.D.
Dr. Francesca Barone, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
100.81K
+4.44%
Mr. Charles Schoch
Mr. Charles Schoch
Chief Financial Officer
Chief Financial Officer
43.39K
+14.07%
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
Independent Director
Independent Director
38.03K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00K
--

収益内蚳

FY2024
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q3
䌚瀟から関連デヌタがただ開瀺されおいたせん。
地域別USD
䌚瀟名
収益
比率
United States
0.00
0.00%
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Sun, Nov 16
曎新時刻: Sun, Nov 16
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
Fidelity Management & Research Company LLC
15.00%
Manning (Paul B.)
5.14%
Acorn Capital Advisors, LLC
4.70%
Aguilar-Cordova (Estuardo)
4.41%
Aguilar (Laura K)
4.29%
他の
66.46%
株䞻統蚈
株䞻統蚈
比率
Fidelity Management & Research Company LLC
15.00%
Manning (Paul B.)
5.14%
Acorn Capital Advisors, LLC
4.70%
Aguilar-Cordova (Estuardo)
4.41%
Aguilar (Laura K)
4.29%
他の
66.46%
皮類
株䞻統蚈
比率
Investment Advisor
31.39%
Individual Investor
15.75%
Investment Advisor/Hedge Fund
7.98%
Corporation
2.37%
Hedge Fund
1.84%
Research Firm
0.31%
Bank and Trust
0.12%
Pension Fund
0.11%
他の
40.13%

機関投資家保有株


曎新時刻: Mon, Dec 8
曎新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q4
162
22.92M
49.81%
+771.00
2025Q3
163
22.99M
50.01%
-379.95K
2025Q2
155
23.37M
48.18%
+1.99M
2025Q1
149
21.38M
48.85%
-1.70M
2024Q4
121
18.49M
19.46%
+11.29M
2024Q3
102
7.20M
24.25%
+733.84K
2024Q2
85
6.85M
21.09%
+2.44M
2024Q1
54
4.66M
22.51%
-1.95M
2023Q4
53
4.83M
23.41%
-1.22M
2023Q3
56
6.00M
23.34%
-100.58K
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
Fidelity Management & Research Company LLC
8.23M
15%
+1.15M
+16.20%
Jun 30, 2025
Manning (Paul B.)
2.82M
5.14%
+500.00K
+21.52%
Apr 21, 2025
Acorn Capital Advisors, LLC
2.58M
4.7%
+428.26K
+19.90%
Jun 30, 2025
Aguilar-Cordova (Estuardo)
2.42M
4.41%
+190.92K
+8.57%
Apr 21, 2025
Aguilar (Laura K)
2.36M
4.29%
-690.05K
-22.65%
Apr 21, 2025
BlackRock Institutional Trust Company, N.A.
2.09M
3.8%
+480.45K
+29.91%
Jun 30, 2025
The Vanguard Group, Inc.
1.79M
3.26%
+51.45K
+2.96%
Jun 30, 2025
Portolan Capital Management, L.L.C.
1.62M
2.95%
+740.54K
+84.04%
Jun 30, 2025
BKB Growth Investments LLC
1.30M
2.38%
+750.00K
+135.44%
Apr 21, 2025
Geode Capital Management, L.L.C.
903.97K
1.65%
+216.51K
+31.49%
Jun 30, 2025
詳现を芋る

関連ETF


曎新時刻: Sat, Dec 6
曎新時刻: Sat, Dec 6
銘柄名
比率
ALPS Medical Breakthroughs ETF
0.12%
iShares Micro-Cap ETF
0.04%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
Vanguard US Momentum Factor ETF
0%
iShares Russell 2000 Value ETF
0%
詳现を芋る
ALPS Medical Breakthroughs ETF
比率0.12%
iShares Micro-Cap ETF
比率0.04%
iShares Russell 2000 ETF
比率0.01%
ProShares UltraPro Russell2000
比率0.01%
iShares Russell 2000 Growth ETF
比率0.01%
Proshares Ultra Russell 2000
比率0.01%
Global X Russell 2000 ETF
比率0.01%
ProShares Hedge Replication ETF
比率0.01%
Vanguard US Momentum Factor ETF
比率0%
iShares Russell 2000 Value ETF
比率0%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
皮類
比率
デヌタなし
日付
皮類
比率
デヌタなし

よくある質問

Candel Therapeutics Incの䞊䜍5名の株䞻は誰ですか


Candel Therapeutics Incの䞊䜍5名の株䞻は以䞋のずおりです。
Fidelity Management & Research Company LLCは8.23M株を保有しおおり、これは党䜓の15.00%に盞圓したす。
Manning (Paul B.)は2.82M株を保有しおおり、これは党䜓の5.14%に盞圓したす。
Acorn Capital Advisors, LLCは2.58M株を保有しおおり、これは党䜓の4.70%に盞圓したす。
Aguilar-Cordova (Estuardo)は2.42M株を保有しおおり、これは党䜓の4.41%に盞圓したす。
Aguilar (Laura K)は2.36M株を保有しおおり、これは党䜓の4.29%に盞圓したす。

Candel Therapeutics Incの株䞻タむプ䞊䜍3皮は䜕ですか


Candel Therapeutics Incの株䞻タむプ䞊䜍3皮は、
Fidelity Management & Research Company LLC
Manning (Paul B.)
Acorn Capital Advisors, LLC

Candel Therapeutics IncCADLの株匏を保有しおいる機関の数はいく぀ですか


2025Q4時点で、Candel Therapeutics Incの株匏を保有しおいる機関は162瀟あり、保有株匏の総垂堎䟡倀は玄22.92Mで、党䜓の49.81%を占めおいたす。2025Q3ず比范しお、機関の持ち株は-0.20%増加しおいたす。

Candel Therapeutics Incの最倧の収益源は䜕ですか


FY2024においお、--郚門がCandel Therapeutics Incにずっお最倧の収益を生み出しおおり、その金額は--で、党収益の--%を占めおいたす。
KeyAI
î™